Cocaine use disorder (CUD) remains a significant public health challenge. L-Tetrahydropalmatine (L-THP), a well-tolerated and nonaddictive compound, shows promise for the management of CUD. Its pharmacologic profile includes blockade at dopamine and other monoamine receptors and attenuation of cocaine self-administration, reinstatement, and rewarding properties in rats. This study evaluated the safety of L-THP in human cocaine users and its influence on the safety and pharmacokinetics (PK) of cocaine. Twenty-four cocaine-using adult men were randomized to receive L-THP (30 mg twice a day orally) or placebo double-blind for 4 days, with an intranasal cocaine (40 mg) challenge on the fourth day. Safety and tolerability were evaluated using vital signs, ECG, clinical laboratory tests, and standardized self-report instruments. Peripheral venous blood was collected periodically and later assayed for L-THP and cocaine using highly sensitive and specific ultraperformance liquid chromatography-fluorescence detection (UPLC-FLD) methods. Twenty subjects completed the study, of whom 19 provided complete PK data. The short 3.5-day course of L-THP was safe and well tolerated and did not affect cocaine's PK or its acute cardiovascular effects. The cocaine AUC 0→Ý was 211.5 and 261.4 h·ng/mL, and the C max was 83.3 and 104.5 ng/mL for the L-THP and placebo groups, respectively. In addition there were no significant differences in the number of side effects reported in each group (L-THP group 22 [48%], placebo group 24 [52%]) or vital signs including, heart rate, blood pressure, complete blood count, or ECG. These findings suggest that oral THP has promise for further development as a treatment for CUD.
Cocaine use and addiction (cocaine use disorder [CUD] in DSM-5 terms) 1 remain significant public health problems in many regions of the world. Cocaine is used annually by an estimated 17 million people worldwide, 0.4% of the global population 15-64 years old. 2 In the United States there were an estimated 1.5 million cocaine users in 2013. An estimated 550,000 Americans had CUD in 2013; fewer than 600,000 received specialty treatment for a cocaine use problem. 3 Cocaine use was mentioned in an estimated one-half million emergency department visits in 2011, about one-fifth of all drug/medication-related visits. 4 Cocaine-related problems are likely to continue in the future, as an estimated 1300 people initiate cocaine use in the United States each day (500,000 in 2013). 3 Despite this compelling need for effective treatment modalities for CUD and decades of intensive research, there is still no wellproven, broadly effective treatment, and no medication is approved for the treatment of CUD by the US FDA or any national regulatory authority. [5] [6] [7] [8] [9] There is one compound that shows particular promise as a new treatment for CUD: levotetrahydropalmatine (L-THP), an alkaloid isolated from the Chinese plant Corydalis yanhusuo. Corydalis has historically been used in Chinese medicine for its analgesic and hypnotic properties, which have been attributed to L-THP. 10 L-THP is a D 1 , D 2 , and D 3 receptor antagonist in vitro, 11, 12 an antagonist at α 1 adrenergic receptors and several 5-HT receptors, 13 and an enhancer of GABAergic transmission. 14 The unique pharmacologic profile of L-THP provides rationale for its potential to treat CUD. In particular, dopamine D 3 receptor antagonists show promise in rodent models of cocaine addiction; ie, they reduce cocaine self-administration, relapse to previously extinguished cocaine self-administration, and rewarding effects of cocaine. [15] [16] [17] However, to date, no D 3 antagonist compound has proceeded through human trials because of pharmacokinetic or toxicity problems. 16 In addition, the anxiolytic properties of L-THP may alleviate drug withdrawal symptoms and make it easier for users to abstain. An in-depth review detailing the rationale for investigating L-THP for treating CUD has been previously published. 18 Several animal studies support the therapeutic potential of L-THP. L-THP readily penetrates the bloodbrain barrier (BBB), 19 reduces self-administration of cocaine, and prevents drug-or stress-induced reinstatement of previously extinguished cocaine selfadministration (an animal model of relapse) in rats. 12, [20] [21] [22] [23] A Chinese phase 1 clinical trial involving L-THP (60 mg orally) in 12 healthy men found a mean T max of 1.25 ± 0.59 hours, C max 0.19 ± 0.036 μg/mL, and elimination half-life 11.42 ± 2.43 hours. 24 A Chinese double-blind phase 2 clinical trial found that L-THP (30 mg twice a day [BID] for 4 weeks) in inpatient heroin users reduced craving and relapse to heroin use after discharge from the hospital. 25 No study of L-THP has been performed in cocaine users. The goal of this phase 1 clinical trial was to evaluate the safety, tolerability, and pharmacokinetics (PK) of oral L-THP in chronic cocaine users in the presence and absence of cocaine, with the aim of developing L-THP for phase 2 clinical trials to further evaluate its efficacy for the treatment of CUD.
Methods

Enrollment
The study was approved by the investigational review board (IRB) at the University of Maryland, Baltimore (UMB) and was registered at ClinicalTrials.gov (NCT01631383). All subjects gave written informed consent (when not acutely intoxicated) prior to starting study procedures. Participants were healthy, cocaineusing adults recruited from the community by media advertising and screened initially by telephone, then in person with a comprehensive psychological and medical evaluation. Inclusion criteria included men or nonpregnant/nonbreastfeeding women age 18-50 years old with current CUD, self-reported cocaine use averaging at least weekly for the past 6 months, positive urine test for cocaine in the last month, HIV seronegative, ECG without clinically significant abnormality, normal blood pressure (90-140/50-90 mmHg), normal resting heart rate (60-90 bpm), ability to adhere to study restrictions and examination schedule, and contraception use during and for 2 weeks after the study by women with reproductive potential. Exclusion criteria included participation in any drug trial within 45 days prior to study entry, history of clinically significant adverse reaction or hypersensitivity to L-THP or cocaine, inability to communicate or cooperate with investigators, currently taking any prescribed psychoactive medication, current clinically significant medical problem that might interfere with safe study participation, current major depressive disorder, current schizophrenia, current bipolar disorder, or a score below 10/12 on the Evaluation to Sign Consent (ESC) questionnaire. 26 
Study Design
This study followed a randomized, double-blind, placebo-controlled design. Subjects participated while residing for 5 days/4 nights on a secure, medically monitored Brief Stay Unit (BSU) designed for phase 1 studies. Subjects were randomized to receive either L-THP (30-mg capsules every 12 hours [Q12h]) or matching placebo for 7 doses (study days 1-4) starting the morning of the day of admission (study day 1). Ninety minutes following the final dose (morning of day 4) subjects received a single 40-mg intranasal dose of cocaine. The L-THP dosing duration was chosen to have participants reach steady-state L-THP plasma concentration approximately 24 hours prior to cocaine challenge, based on an L-THP half-life of 11 hours. 24 Subjects resided on the BSU from the morning of day 1 until the evening of day 5, then returned for a final blood collection and safety evaluation on day 6 (Table 1) .
Study Medications
Bulk L-THP was purchased from Wuxi Gorunjie Technology Co, Ltd. (Wuxi, Jiangsu, 214044 China), and L-THP and matching placebo capsules were prepared at the University of Maryland School of Pharmacy (UMSOP) in compliance with Chemistry, Manufacturing and Controls (CMC) standards.
Cocaine hydrochloride USP was obtained through the National Institute on Drug Abuse (NIDA) Drug Supply Program from Covidien, meeting the guidelines for CMC standards. For the cocaine challenge at 9 AM on day 4, 40 mg of cocaine powder was weighed and placed on a mirror in front of the seated subject. The subject divided the powder into 2 approximately equal lines using a spatula, then inhaled each line into a different nostril using a 65-mm plastic straw. Subjects had up to 5 minutes to ingest each line (all took <1 minute) and waited 4 to 6 minutes between lines to allow for checking of vital signs and 12-lead ECG with 3-minute rhythm strip.
Randomization and Blinding
The study biostatistician used the permuted block method of randomization to generate multiple sequences (blocks) of size 4, with 2 participants each assigned to L-THP or placebo. When a new participant met study eligibility criteria and gave informed consent, the study coordinator requested a randomization from the study biostatistician, who responded by sending a code number to the unblinded study pharmacist identifying the next randomization in the sequence. The pharmacist prepared the appropriate dose of L-THP or placebo and provided this to the study coordinator in a package labeled "L-THP or Placebo, 30-mg capsules Q12h." Only the study biostatistician and the pharmacist were aware of the actual contents of the package: the participant and all other study personnel remained blinded.
L-Tetrahydropalmatine and Cocaine Assays
Blood samples (5 mL) were obtained via an indwelling peripheral venous catheter before each L-THP dose, 2 hours before cocaine administration (day 4), and then every 10 minutes for 2 hours, every 30 minutes for 2 hours, every hour for 3 hours, and then at 10, 22, 28.5, and 53.5 hours after cocaine administration. Table 1 shows blood-sampling details. Samples were collected into Vacutainer R tubes (BD Diagnostics, Franklin Lakes, New Jersey) containing EDTA and NaF and centrifuged at 3000 rpm for 15 minutes, and the separated plasma was transferred immediately into plastic Eppendorf TM tubes (Fisher Scientific, Hampton, New Hampshire) for storage at -80 0 C until later assay within 5 days. Plasma concentrations of cocaine and L-THP were measured by the UMSOP Pharmacokinetics and Biopharmaceutics Laboratory (PBL) using a previously validated ultraperformance liquid chromatography-fluorescence detection (UPLC-FL) analysis method developed by our group. 27 Assay limit of quantification (LOQ) was 2.5 ng/mL for both L-THP and cocaine.
Noncompartmental Analysis of L-Tetrahydropalmatine and Cocaine PK parameters were initially determined using a modelindependent approach, noncompartmental analysis (NCA), with estimation of AUCs by linear trapezoidal method using Phoenix WinNonlin 6.4 (Pharsight Corporation, Cary, North Carolina) that was validated using Phoenix Validation Suite 2.2.7.0 (Pharsight Corporation, Cary, North Carolina). PK analysis was performed using the actual times that individual blood samples were obtained and their actual measured analyte concentrations. PK parameters (geometric means) estimated included maximum observed plasma concentration (C max ), time of C max (T max ), terminal halflife (t 1/2 ), area under the plasma concentration-time curve from time 0 up to the time of the last quantifiable sample estimated (AUC 0-last) , area under the plasma concentration time curve from time 0 up to infinity (AUC 0-Ý ), and clearance following oral or intranasal administration (CL/F), where F is defined as bioavailability. Statistical comparisons of cocaine PK parameters with and without exposure to L-THP were conducted by 2-sample t-tests, assuming unequal variance, with GraphPad Prism version 5.04 (GraphPad Software, Inc, La Jolla, California). Statistical significance was set at 2-tailed α = 0.05.
Safety and Tolerability Assessments
We measured a variety of safety outcomes to determine short-term tolerability of L-THP using the following scales: Barnes Akathisia Scale (BAS) to assess objective and subjective components of akathisia 28 ; the Simpson-Angus Scale (SAS) to assess extrapyramidal symptoms 29 ; Epworth Sleepiness Scale (ESS) 30 to assess sedation; Symptom Checklist-90 item Revised (SCL-90R) 31 to assess psychological symptoms, analyzed in terms of Global Severity Index (GSI) and 4 subscales: Depression, Anxiety, Paranoid Ideation, and Psychoticism; Side Effect Checklist (SEC), a 25-item, self-report scale assessing side effects associated with L-THP and nonspecific side effects. Each item was rated on a 4-point Likert scale: "none" = 1, "mild" = 2, "moderate" = 3, and "severe" = 4.
Vital signs (systolic [SBP] and diastolic [DBP] blood pressure, heart rate [HR], respiratory rate) and 12-lead ECG were assessed by standard clinical technique on admission to the BSU (day 1) prior to administration of any study medication (baseline for L-THP safety and tolerability analyses). ECG was performed again 3 and 12 hours after the initial L-THP dose on day 1. Pulse and blood pressure were measured periodically during waking hours and at night for the duration of the residential stay.
Clinical laboratory tests (complete blood count [CBC], thyroid-stimulating hormone [TSH] , and blood chemistry panel) were performed on admission to the BSU and then each morning (fasting) for the next 3 days (days 2-4).
On the morning of day 4, prior to the last dose of L-THP and initiation of cocaine challenge, vital signs and ECG were assessed to determine baseline values for cocaine safety. Ninety minutes after L-THP or placebo administration, the participant selfadministered cocaine by insufflation in the presence of an Advanced Cardiac Life Support (ACLS)-certified physician and nurse. Heart rate (ECG chest lead) was continuously monitored from approximately 5 minutes before to 2 hours after cocaine dosing or until values returned to within 20% of baseline values, whichever was later. Blood pressure and heart rate were monitored approximately every 15 minutes from 5 minutes prior to cocaine dosing until 2 hours after dosing, then every Figure 1 . Flowchart of subjects included in PK analysis. One participant initially enrolled in the L-THP group was withdrawn on study day 3 due to an upper respiratory infection and was later reenrolled, randomly reassigned to the L-THP group, and completed the study. This participant has been counted twice, resulting in n = 24 randomized and allocated to treatment.
30 minutes for 3 hours, and then every 2 hours for 6 hours. Twelve-lead ECGs were completed immediately following cocaine administration and then at 1, 2, 4, and 10 hours postadministration. Clinical laboratory tests were performed at follow-up (day 6).
Sample Size and Power
For this phase 1 study, sample size was determined by the need for adequate power to detect a potential drug-drug interaction between cocaine and L-THP that would dangerously elevate the acute cardiovascular (heart rate and/or blood pressure) response to cocaine administration, which was determined in consultation with the FDA to be the most serious safety question posed by the use of L-THP in cocaine-using participants. Had all 24 randomized participants completed the study, there would have been power = 0.80 to detect a 0.2 standard deviation increase in peak change in HR, SBP, or DBP (each tested at 2-sided α = 0.05); with only 20 participants completing the exposure to cocaine plus L-THP or placebo, there was power = 0.80 to detect an 0.32 standard deviation increase in these measures.
Data Analysis
Baseline Characteristics and Safety/Tolerability Data. Baseline participant characteristics (Table 2) in the 2 medication groups were compared with a Wilcoxon test for categorical variables and t-test for quantitative variables. The primary between-group comparison for cardiovascular, laboratory tests, SCL-90R, and ESS variables was the peak change from baseline for each subject, adjusted for baseline value using ANCOVA. Baseline was defined as the morning of admission (day 1) prior to the first dose of L-THP or placebo. The endpoint for safety and tolerability data was the evening of day 3 for completers or the last measurement before withdrawal. Between-group comparisons for movement assessments and side effects were based on the proportion of participants in each group showing an increase in severity from baseline, using the Fisher exact test. For the BAS, an increase was considered at least a 2-point increase from a 0 baseline or at least a 1-point increase from a higher baseline. For the SAS, an increase was considered at least a 2-point increase in total score. For the day 4 safety data relating to cocaine administration, we used the morning values prior to L-THP administration as the baseline, calculated maximal change from baseline, and compared the peak change between medication groups using the Student t test. All statistical comparisons used a 2-tailed α = 0.05 and were conducted with SAS version 9.3 (SAS Institute, Cary, North Carolina).
Results
Subjects
A total of 151 candidates were screened by telephone, 55 of whom were preliminarily qualified and screened in person (Figure 1 ). Of the 55 candidates screened, 27 failed to meet the eligibility criteria, and 5 were excluded for other reasons. A total of 23 unique individuals were enrolled in the study between January and December 2013. One subject, subject L (L-THP group), was removed from the study on day 3 but later reenrolled as subject D (L-THP group). The 2 study periods for this individual were treated as 2 separate subjects for purposes of analyzing L-THP safety and PK data, bringing the total number of subjects randomized to study medication to 24 ( Figure 1 ). Subjects' baseline demographic and substance use histories are presented in Table 2 .
Of the 24 subjects enrolled, 20 completed the study per protocol, and 4 were withdrawn prior to cocaine administration. One subject, X (placebo group), was withdrawn on day 1 (ECG changes), and 3 subjects were withdrawn on day 3 (prior to receiving cocaine): E (ECG changes) and L (upper respiratory infection), both L-THP group, and M (ECG changes), placebo group. All withdrawals were deemed unrelated to the study drug.
Of the 20 subjects who completed the protocol, samples from 19 subjects (9 subjects in the L-THP group; 10 subjects in the placebo group) were available for complete PK analysis. Samples from subject B (L-THP group) were available on days 1 through 3; samples on days 4 through 6 could not be analyzed due to coagulation. There were no significant differences between medication groups in participant baseline characteristics (Table 2 ) or in the number of participants not completing the study. Figure 1 shows a flow chart of subject enrollment and completion.
Noncompartmental PK Analysis L-Tetrahydropalmatine. Plasma concentrations of L-THP rose rapidly after the first dose, with a geometric mean C max of 42.8 ng/mL and median T max of 1.5 hours (Table 3) . Data from 3 subjects (B, E, and L) were included in calculating the geometric mean of C max and the median T max but were excluded from other Thyroid-Stimulating Hormone (uIU/mL) (TSH) Baseline 1.7 ± 1.3 1.7 ± 0.9 PK analyses due to missing data after day 3: blood coagulated (B), or no samples were collected due to withdrawal from the study (E and L). The accumulation ratio of L-THP was calculated to be 1.2 using AUC 0-12 .
Cocaine. There were no significant differences in the PK parameters of cocaine (40 mg intranasal) administered after 3.5 days of L-THP (L-THP group) or of placebo (placebo group) ( Table 3 ). The mean plasma cocaine concentration-vs-time plots were similar for both groups (Figure 2 ) .
No subject had measurable plasma cocaine concentration by day 5; therefore, only data from day 4 were included for cocaine PK analysis. At follow-up on day 6, subjects H and N had unexpectedly high plasma cocaine concentrations, which were assumed to be the result of cocaine self-administration after discharge on day 5 (excluded from PK analysis). Cocaine was detected in the plasma of 4 subjects on day 4 prior to cocaine administration: 3 subjects (D, G, and V) had very low concentrations (<6 ng/mL); 1 subject (J) had a concentration of 26.2 ng/mL, which was verified by reassay. Plasma cocaine present at baseline was assumed due to cocaine self-administered in the community prior to admission. A reanalysis excluding all 4 subjects with cocaine present before cocaine administration on day 4 also indicated no significant differences in cocaine PK parameters between the L-THP and placebo groups.
Safety of L-Tetrahydropalmatine (Days 1 Through 3)
Seventeen (71%) participants reported a total of 46 side effects after exposure to study medication: 9 on L-THP (22 [48%] side effects) and 8 on placebo (24 [52%] side effects) (Table S1 ). All side effects were nonserious and resolved completely without sequelae before the participants left the study.
Sleepiness and Psychological Symptoms. There were no significant differences between L-THP and placebo groups in the mean (±SD) maximum change from baseline of the ESS scores or the Symptom Checklist-90-R Global Severity Index or the anxiety, depression, paranoia, and psychoticism subscales (Table 4) .
Vital Signs and Laboratory Values. There were no significant differences between L-THP and placebo groups in mean maximum change from baseline for heart rate, systolic and diastolic blood pressure, individual tests of complete blood count, clinical chemistry panel, or ECG QTcB interval (Table 5) . All values for each variable were within the expected "normal" range.
Safety of Cocaine Challenge (Day 4)
All 20 subjects completed the cocaine challenge; no participant had any clinically significant changes in vital signs or ECG parameters after ingestion of the first 20 mg or the cumulative 40-mg dose. There were no significant differences in change from baseline after cocaine challenge of these safety parameters between the L-THP and placebo groups (Table S2) . No side effects were attributed to the cocaine challenge.
Discussion
Our goal was to characterize the safety/tolerability and PK profile of oral L-THP and intranasal cocaine and their interaction in otherwise healthy cocaine-using adult men. To the best of our knowledge, this is the first study to characterize the safety and PK profile of L-THP in cocaine users and to assess the L-THPcocaine interaction.
Exposure to L-THP for 3.5 days had no significant effect on the PK profile of or acute cardiovascular response to a 40-mg intranasal cocaine challenge (Table 3 , Figure 2 ), indicating that short-term L-THP administration does not significantly alter the PK or acute cardiovascular effects of cocaine. The PK profile of oral L-THP in our study sample of largely African-American adult cocaine-using men was similar to that previously reported in Chinese adults, either healthy 24 or with opiate abuse, 25 suggesting that a similar PK profile would most probably be found in the heterogeneous US population. Because our cocaine-using subjects had normal liver function and normal levels of serum proteins, it is unlikely that variations in L-THP binding contributed to the observed intersubject variability in L-THP PK parameters. Comparable pharmacokinetic parameters for L-THP were observed for clearance (75.7 and 59.9 L/h), terminal half-life (13.3 and 11.4), AUC 0-Ý (396.1 and 1000 h·ng/mL), T max (1.5 and 1.25 hours), and C max (42.8 and 190 ng/mL) between cocaine users (30-mg L-THP tablet) and healthy adults (60-mg L-THP disintegrating tablet), respectively. 24 Taken together, these findings suggest the safety of L-THP as a potential treatment for CUD and support further research toward this end.
We found 2 distinct peaks of cocaine concentration following intranasal administration, as previously reported. 32 This is presumably due to some of the intranasal dose being swallowed, resulting in a delayed absorption across the gastric mucosa, in addition to the immediate absorption across the nasal mucosa. This difference may be due to inconsistencies in insufflation technique among subjects. Six (32%) subjects exhibited the second peak associated with gastrointestinal absorption of the cocaine dose. It is likely that subjects who absorbed lesser amounts of cocaine through the nasal mucosa exhibited the second peak.
Limitations of this study include evaluation of single doses of L-THP and cocaine (precluding full evaluation of the potential interaction), and homogeneity (100% men, 84% cigarette smokers, 70% African-American), and small size (19 subjects, of whom only 9 received L-THP) of the study sample, which reduced external validity and the ability to evaluate PK associations with subject characteristics. Strengths of this study include the randomized, double-blind design and detailed characterization of PK parameters.
Our study found that the safety profile of cocaine was not affected by short-term L-THP administration. There was an expected increase in blood pressure and heart rate following cocaine administration that was not influenced by L-THP (Table S2) . Furthermore, L-THP did not affect the QTc interval. Although hepatotoxicity has been associated with L-THP and L-THP-containing supplements, 33, 34 this study showed no difference in liver transaminase levels between participants receiving L-THP and those receiving placebo (Table 5 ). However, we cannot rule out the possibility of hepatotoxicity from L-THP administration longer than 3.5 days, as would be the case for CUD treatment. L-THP has been reported to have sedating effects, 18 but we did not observe any significant differences between the L-THP and placebo groups in Epworth Sleepiness Scale scores, suggesting that the dose of L-THP used was not significantly sedating.
Conclusion
In conclusion, our study found that oral L-THP was safe and well tolerated in adult male cocaine users and did not affect the PK of cocaine. This provides strong evidence of the safety of L-THP and highlights its potential for further assessment in phase 2 clinical trials to evaluate its efficacy for treatment of CUD.
